

External Innovation

We are a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. To accomplish our mission, we are looking into various possibilities, and partnering plays an important strategic role in executing our R&D strategy, evolving our portfolio and growth. Under this strategy, Bristol Myers Squibb Japan (BMS Japan) actively engage in external innovation activities.

We are actively seeking for partnering opportunities with Japanese academia, research institutes and biotechs with drug seeds from early to late stages of development.

Furthermore, BMS Japan has a unique collaboration platform to support drug development of academic seeds of Japan. (Please refer to "Evaluation Process" for more details)

Therapeutic Areas of Focus



SOLID TUMORS



HEMATOLOGY



CARDIOVASCULAR



IMMUNOLOGY



FIBROTIC
DISEASES



NEUROSCIENCE

Cross-therapeutic Areas of Focus



TRANSLATIONAL
MEDICINE



DIGITAL HEALTH



CELL THERAPY




RESEARCH
TECHNOLOGIES

[For further details, download our Partnering Brochure \(EN\)](#)

Evaluation Process

1. Application	Please apply via e-mail with the required information (non-confidential).
2. Primary evaluation	Based on the non-confidential information that we receive, we will evaluate your research proposal based on the details, novelty, and collaboration possibility. Please note that the evaluation process will take approximately 3 weeks.
3. Secondary evaluation	We will arrange a meeting to evaluate the details of the research. We may ask you to sign a non-disclosure agreement before the meeting, if necessary.
4. Collaboration	<p>We will offer collaboration options based on your research:</p> <ul style="list-style-type: none"> ● Drug development support by BMS Japan: We will support early-stage research proposals from academia so that the research can be led to future research collaboration with BMS Global or in-licensing. ● Research collaboration with BMS Global: Late-stage research proposals from academia and biotech companies ● In-Licensing: Assets under development by biotech companies



For submission of proposal(s) using Bristol Myers Squibb products, please refer to our BMS US website: <http://www.bms.com>

How to apply

If you would like to send us opportunities for future research collaborations and/or on novel therapeutic seeds, please contact the Open Innovation Organizing Team via e-mail with the required information below (non-confidential).

- Name
- Affiliation
- Homepage URL (optional)
- Proposal
 - Target therapeutic area
 - Research outline/Non-confidential and disclosable research data to date
 - Data that can be disclosed after a non-disclosure agreement
 - Novelty/Superiority of research
 - Intellectual property
 - Current alliance status
 - What role/responsibility is expected for BMS in the proposal
 - Published articles/literature related to the research (optional)
 - Attachments (optional)

Open Innovation Organizing Team

bms-join@bms.com

Contact

For application or questions on external innovation, please contact the below address:

Open Innovation Organizing Team

bms-join@bms.com

FAQ

Do I need to apply in English?

Application for primary evaluation may be in Japanese or English, whichever that is preferable, but there may be cases where we will ask you to prepare English material during the evaluation process.

How much details should be included in the research outline?

Please describe the outline of your research so that our Open Innovation Organizing Team can adequately understand the details and uniqueness/superiority of your research.

Also, please do not include any confidential data in the application material for primary evaluation including but not limited to: data of intellectual property that is scheduled for patent application, data from journals and/or reports that have not been published yet.

Can I apply multiple proposals?

Yes. Please apply each proposal separately.

Can I include confidential information in my research outline?

All proposals are basically evaluated based on non-confidential information.

If you wish to have your proposal evaluated based on confidential data, please contact the Open Innovation Organizing Team (bms-join@bms.com) before sending any confidential information.

Handling of personal information

All personal information that is sent to Bristol Myers Squibb will be handled properly, and will only be used for evaluation, registration and administrative purposes of our external innovation activities. In our evaluation, registration and administrative purposes of our external innovation activities, there may be cases where personal information will be shared with the Bristol Myers Squibb Global Headquarters in the United States of America, and its affiliated companies. For other information on handling of personal information, please refer to the Bristol Myers Squibb Japan privacy policy.

Are there any character limits/file size limits to the research outline?

Please summarize your research outline within 2 pages of A4 size. If you wish to attach files/materials for reference, please make sure the total file size is within 5MB.

Is there a deadline?

No.

Appendix: Evaluation Process

